Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Study Overview

This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer.

The names of the study drugs involved in this study are Niraparib and Osimertinib.

Study Description

Phase 1 Study of Niraparib in Combination with Osimertinib in EGFR-Mutated Advanced Lung Cancer

  • ClinicalTrials.gov Identifier: NCT03891615
  • Protocol Number: 18-613

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000